Key points are not available for this paper at this time.
Levosimendan role in critical care remains uncertain; Level 5 evidence leaves open questions on net clinical benefit.
Department of Anaesthesiology and Intensive Care Medicine; Department of Cardiac Surgery; Klinikum der Stadt Ludwigshafen; Ludwigshafen, Germany Dr. Lehmann was consultant on levosimendan for Orion Pharma, Germany, took part in advisory board meetings on levosimendan, and gave paid lectures on levosimendan. He was paid by Orion Pharma, Germany, and Abbott, Germany. The remaining authors have not disclosed any potential conflicts of interest.
No takes yet. Share an insight, caveat, or question.
Lehmann et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: